Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT):
A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
← Back to available clinical trials
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT):
A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting